If word from usually reliable Bloomberg is to be believed, the managements of GlaxoSmithKline (GSK) and Human Genome Sciences (HGSI) have seen reason and reached an agreement
on a friendly transaction. While this deal is an unconfirmed rumor at
the time of this writing, Glaxo has supposedly upped its offer by a
little less than 10%, to $14 per share or $2.8 billion in cash.
Please read more here:
Glaxo And Human Genome Have Apparently Seen Reason
No comments:
Post a Comment